New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:45 EDTPLXProtalix reported 2013 highlights
Protalix BioTherapeutics reported 2013 highlights. ELELYSO/UPLYSO highlights include: approval in Brazil, Mexico and Chile; in Israel, since the addition of ELELYSO to Israel's national healthcare reimbursement basket in early 2013, ELELYSO has become the drug of choice for na´ve adult Gaucher patients; in Chile, during the Q4 of 2013, all adult Gaucher patients previously treated with other enzyme replacement therapies were successfully switched to UPLYSO/ELELYSO; An application for a pediatric indication of ELELYSO has been submitted to the FDA. The Company also entered into a supply and technology transfer agreement in Brazil for UPLYSO, whereby Fiocruz committed to purchase at least approximately $40M worth of the drug during the first two years of the agreement and at least approximately $40M worth of the drug each subsequent year under the agreement. The first shipment of the drug to Brazil under the agreement with Fiocruz has just been made. The Company reported positive top-line phase I clinical trial results for Oral GCD in Gaucher patients.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
10:27 EDTPLXProtalix offers to produce ZMapp Ebola treatment, i24News reports
Israeli company Protalix offered its resources to help produce ZMapp, the experimental Ebola treatment from privately-held MAPP Pharmaceuticals that has been in short supply, i24News reported previously on September 7. The circulation of a report from, which points back to the prior i24 report on Protalix, may be contributing to the early session strength in in the stock, which is up 18% this morning, according to contacts. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use